Skip Navigation



eCAM Advance Access published online on September 2, 2008
eCAM, doi:10.1093/ecam/nen052
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Ferreira, B. L.
Right arrow Articles by Castro, H. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ferreira, B. L.
Right arrow Articles by Castro, H. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© 2008 The Author(s).
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Comparative Analysis of Viperidae Venoms Antibacterial Profile: a Short Communication for Proteomics

Bruno L. Ferreira1,2, Dilvani O. Santos1,2, André Luis dos Santos1,2, Carlos R. Rodrigues2,3, Cícero C. de Freitas1, Lúcio M. Cabral3 and Helena C. Castro1,2

1Departamento de Biologia Celular e Molecular, Laboratório de Antibióticos, Bioquímica e Modelagem Molecular (LABioMol), IB, 2Cursos de Pós-graduação em Neuroimunologia - IB, e Patologia - HUAP, Universidade Federal Fluminense, CEP 24001-970, Niterói, RJ and 3Laboratório de Modelagem Molecular e QSAR (ModMolQSAR), Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, CEP 21941-590, Rio de Janeiro, RJ, Brazil


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 Acknowledgements
 References
 
Bacterial infections involving multidrug-resistant strains are one of the ten leading causes of death and an important health problem in need for new antibacterial sources and agents. Herein, we tested and compared four snake venoms (Agkistrodon rhodostoma, Bothrops jararaca, B. atrox and Lachesis muta) against 10 Gram-positive and Gram-negative drug-resistant clinical bacteria strains to identify them as new sources of potential antibacterial molecules. Our data revealed that, as efficient as some antibiotics currently on the market [minimal inhibitory concentration (MIC) = 1–32 µg ml–1], A. rhodostoma and B. atrox venoms were active against Staphylococcus epidermidis and Enterococcus faecalis (MIC = 4.5 µg ml–1), while B. jararaca inhibited S. aureus growth (MIC = 13 µg ml–1). As genomic and proteomic technologies are improving and developing rapidly, our results suggested that A. rhodostoma, B. atrox and B. jararaca venoms and glands are feasible sources for searching antimicrobial prototypes for future design new antibiotics against drug-resistant clinical bacteria. They also point to an additional perspective to fully identify the pharmacological potential of these venoms by using different techniques.

Keywords: Agkistrodon – antibiotic – bacteria – Bothrops – Lachesis – snake


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 Acknowledgements
 References
 
Bacterial infections are among the 10 leading causes of death worldwide according to the World Health Organization (1,2). The presence and current emergence of the kept multiple-resistant strains make the risk of these infections become more threatening as the treatment becomes unreachable. In fact, bacterial resistance has been the major factor responsible for increasing morbidity, mortality and health care costs of bacterial infections (1–5). Therefore, new antimicrobials or antibacterial prototypes are continuously necessary for drug design and development for treatment of infections involving multidrug-resistant microorganisms (1,2,6,7).

Snake venoms are a complex mixture of proteins and peptides that display potential biological activities and may lead to the production of new drugs of potential therapeutic value (8,9). A good example is the bradykinin-potentiating peptides (BPPs), which are naturally occurring inhibitors of the somatic angiotensin-converting enzyme (ACE) found in Bothrops jararaca venom (10). The chemical and pharmacological properties of these peptides were essential for the development of captopril, the first active site directed inhibitor of ACE, currently used to treat human hypertension (11).

Lately, several naturally occurring peptides presenting antimicrobial activity have been described in the literature. However, Viperidae snake venoms that are an enormous source of peptides have not been fully explored for searching such biological activity (5,12). Therefore, in this study, we tested the antibiotic profile of four snake venoms from three different genera of Viperidae family (Agkistrodon rhodostoma, Bothrops atrox, B. jararaca and Lachesis muta) against 10 drug-resistant Gram-positive and Gram-negative bacteria clinical strains. Based on captopril history, our purpose is to identify some of these venoms as potential source for finding new and effective antibacterial prototypes.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 Acknowledgements
 References
 
Materials

Each venom was purchased from Sigma (St Louis, MO, USA) and one L. muta venom sample was also obtained from each Brazilian governmental sources—Butantan Institute, SP, Ezequiel Dias Institute, SP and Vital Brazil Institute, RJ, Brazil. The 10 Gram-positive (Enterococcus faecalis, Staphylococcus epidermidis and S. aureus) and Gram-negative (Escherichia coli, Serratia marcenses, Proteus mirabilis, Pseudomonas aeruginosa, Enterobacter cloacae, Acinetobacter calcoaceticus and Klebsiella pneumoniae) drug-resistant clinical bacteria were isolated from patients of the Hospital Antônio Pedro from Fluminense Federal University. All other reagents were from Sigma. After isolation, the bacterial strains were kept frozen in 10% milk-sterilized solution containing 10% glycerin.

Methods

Sensibility Test

The test and MIC were performed according to the National Committee for Clinical Laboratory Standards (NCCLS), in Müeller–Hinton medium as described elsewhere (13). Briefly, the strains were grown at 37°C in Müeller–Hinton medium. Then, 1 µl of the snake venom solutions prepared with sterilized distilled and deionized water (20 mg ml–1) was placed in Whatman disks (5 mm diameter). The disks were put on an exponentially growing plated culture with appropriate dilution to 1.0 x 107 colony forming unit (CFU ml–1), which were then incubated for 24 h at 37°C. The inoculums used in growth method were those where turbidity was equal to 0.5 McFarland Standard. The results were verified by measuring the zones surrounding the disk. Ciprofloxacin and vancomycin were used as positive controls and the halo >15 mm was considered the minimum value for positive antimicrobial activity as it generally leads to a MIC near to that observed for the newest antimicrobials current present on the market (MIC = 1–40 µg ml–1). Vancomycin and ciprofloxacin presented halo 15 ± 2 and 23 ± 2 mm, respectively in the strains tested herein (P<0.005).

MIC Assays

In order to determine the MIC of these snake venoms, we tested them using the macro-dilution broth method as described elsewhere (13). Briefly, after 5 h of the bacterial growth, the culture was diluted to obtain 1.0 x 105 CFU ml–1. The snake venom was added in order to reach a final concentration from 0.5 µg ml–1 to 1024 µg ml–1 and incubated at 37°C for 24 h. MIC was defined as the lowest concentration of venom or antibiotic current on the market preventing visible bacterial growth compared to the positive growth control (medium plus bacteria without venom or antibiotic) that presented high turbidity, and to the negative growth controls (medium alone, medium plus venom or antibiotic and medium plus bacteria plus effective antibiotic) that presented no turbidity. All strains were tested at least in duplicate in four separate experiments and a reference antibiotic (vancomycin) was used as standard (MIC = 2 µg ml–1).

Statistics

The statistical analyses were performed using Microcal Origin 4.0 (MA, USA). The SD and significance (P) were determined by using one-way ANOVA from the same graphic program. Results were considered as significant when P<0.005.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 Acknowledgements
 References
 
Sensibility Assays of Viperidae Venoms

Our experimental data revealed that most of the venoms tested (A. rhodostoma, B. atrox and B. jararaca) exhibited an antibacterial profile against some of the Gram-positive bacteria (Table 1). The L. muta venom showed no antibacterial activity (Table 1) even when it was obtained from different Brazilian suppliers (Instituto Butantan, Ezequiel Dias and Vital Brazil) (data not shown).


View this table:
[in this window]
[in a new window]

  		Table 1. Antibacterial effect of Viperidae venoms against Gram-positive and Gram-negative drug-resistant clinical bacteria

 
Agkistrodon rhodostoma was not significantly effective against S. aureus and E. coli (Table 1). However, this venom was able to significantly inhibit E. faecalis and S. epidermidis growth (halo = 16 and 16 mm, respectively). Bothrops atrox venom also showed an antibiotic profile against E. faecalis and S. epidermidis (halo = 16 and 18 mm, respectively), different from B. jararaca venom, which acted only against S. aureus (halo = 16 mm) (Table 1). In addition, Bothrops venoms (B. atrox and B. jararaca) inhibited growth of Staphylococcus sp. (S. epidermidis and S. aureus, respectively).

MIC Assays of the Active Snake Venoms

The MIC assays of the snake venoms that were active in the sensibility tests (A. rhodostoma, B. atrox and B. jararaca) revealed that their level of antibiotic activity was comparable (MIC = 4.5–13 µg ml–1) (Table 2). Agkistrodon rhodostoma and B. atrox were also analogous to the antibiotics currently in use against S. epidermidis, such as ampicillin, chloramphenicol, vancomycin, oxacillin and penicillin G (MIC = 1–32 µg ml–1) (Fig. 1).


View this table:
[in this window]
[in a new window]

  		Table 2. MIC of Viperidae venoms presenting halo >15 mm

 

Figure 1
View larger version (7K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Figure 1. MIC of Viperidae venoms presenting halo >15 mm.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
Acknowledgements
 References
 
Our experimental data revealed that most of the venoms tested (A. rhodostoma, B. atrox and B. jararaca) exhibited a promising antibacterial activity against some of the Gram-positive bacteria. Interestingly, despite of the presence of a known phospholipase A2 (14), the L. muta venom showed no antibacterial activity. Although literature described that different snake may present an individual pattern (5), L. muta different venom samples obtained from three different Brazilian suppliers (Governmental Institutes—Butantan, Ezequiel Dias and Vital Brazil) were not able to affect the bacterial strains (data not shown). This negative result reinforce the fact that the presence of enzymes in the snake venoms do not guarantee the antibiotic profile of these materials as the bacteria cell wall may avoid or affect the actions of these proteins against them.

Differently from A. contortrix venom (12), A. rhodostoma venom was able to significantly inhibit E. faecalis and S. epidermidis growth, which may suggest a specific mechanism or molecule of A. rhodostoma on affecting them.

Bothrops atrox venom also showed an antibiotic profile against E. faecalis and S. epidermidis, different from B. jararaca venom, which acted only against S. aureus. Recently, the literature described L-amino acid oxidases (L-MAO) isolated from B. pirajai (15) and B. alternatus venoms (16) able to inhibit E. coli growth. Our result pointed to the L-MAO isoforms presence in Bothrops sp. venoms as preserved components similar to C-type lectin-like proteins (17). However, as the active profile of these venoms switched to different strains and not included E. coli, our result may also suggest that other antibacterial components may be present in these venoms resulted from species differentiation. In addition, Bothrops venoms (B. atrox and B. jararaca) acted against different Staphylococcus sp. (S. epidermidis and S. aureus, respectively) once again suggesting that different molecules and/or targets are involved in these biological activities. This hypothesis is reinforced by the presence of other different components found in snake venoms that sometimes are involved in a similar biological activity as RGD-peptides and some C-type lectin-like proteins from B. jararaca venom that are both platelet aggregation inhibitors (9).

Overall, our MIC assays revealed that the activity of the venoms tested was comparable (MIC = 4.5–13 µg ml–1) among them. Agkistrodon rhodostoma and B. atrox were also analogous to the antibiotics currently in use against S. epidermidis, such as ampicillin, chloramphenicol, vancomycin, oxacillin and penicillin G (MIC = 1–32 µg ml–1). Presently, S. epidermidis is an important nosocomial pathogen, drastically affecting immunocompromised patients and/or those with indwelling devices, such as joint prostheses, prosthetic heart valves and central venous catheters (18). Therefore, these venoms’ active profile against this strain is of interest for pursuing continuously an antibacterial molecule.

Proteomic technologies are improving and developing rapidly (19). An important goal of proteomic studies of snake venoms is discovering molecules that may be used in treatment of diseases or as drugs prototypes. Nevertheless, these techniques may depend on the experimental data generated so far to identify some of these unknown proteins or peptides. Although snake venom peptides and proteins have a limited direct therapeutical use due to their antigenic and ‘digestible’ structure, their usefulness as prototypes has clear potential (9,20). Our data suggested that A. rhodostoma, B. atrox and B. jararaca are feasible sources for searching antimicrobial prototypes and designing new antibiotics against drug-resistant clinical bacteria, and these data may act as a start for investing on these venoms proteomic study for prototypes searching.


  Footnotes
 
For reprints and all correspondence: Helena Carla Castro, Departamento de Biologia Celular e Molecular, Laboratório de Antibióticos, Bioquímica e Modelagem Molecular (LABioMol), Instituto de Biologia, CEG, Universidade Federal Fluminense, CEP 24001–970, Niterói, RJ, Brazil. Tel: +55-021-26292294; Fax: +55-021-26292284; E-mail: hcastrorangel{at}vm.uff.br


   Acknowledgements
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Acknowledgements
References
 
The authors would like to thank Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Universidade Federal Fluminense (UFF) and Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ) from Brazil for the financial support and fellowships of H.C.C. They also thank L. C. Correa for his technical assistance.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Acknowledgements
 References
 

  1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJL. Global Burden of Disease and Risk Factors ( 2006;) Washington: IBRD/The World Bank and Oxford University Press.
  2. World Health Organization, WHO. Department of Communicable Disease Surveillance, World Health Organization, Department of Essential Drugs and Medicines Policy. Available at: http://www.who.int/en/ (date last accessed January 10, 2007).
  3. Barbosa TM, Levy SB. The impact of antibiotic use on resistance development and persistence. Drug Resist Updat ( 2000;) 3:: 303–11.[CrossRef][Web of Science][Medline]
  4. Ang JY, Ezike E, Asmar BI. Antibacterial resistance. Symp Ser Soc Appl Microbiol ( 2004;) 71:: 229–39.
  5. de Lima DC, Alvarez Abreu P, de Freitas CC, Santos DO, Borges RO, Dos Santos TC, et al. Snake venom: any clue for antibiotics and CAM? Evid Based Complement Alternat Med ( 2005;) 2:: 39–47.[Abstract/Free Full Text]
  6. Guardabassi L, Kruse H. Overlooked aspects concerning development and spread of antimicrobial resistance. Expert Rev Anti Infect Ther ( 2003;) 1:: 359–62.[CrossRef][Medline]
  7. Roos KL. Emerging antimicrobial-resistant infections. Arch Neurol ( 2004;) 61:: 1512–4.[Free Full Text]
  8. White J. Bites and stings from venomous animals: a global overview. Ther Drug Monit ( 2000;) 22:: 65–8.[CrossRef][Web of Science][Medline]
  9. Koh DC, Armugam A, Jeyaseelan K. Snake venom components and their applications in biomedicine. Cell Mol Life Sci ( 2006;) 63:: 3030–41.[CrossRef][Web of Science][Medline]
  10. Ferreira SH, Bartelt DC, Greene LJ. Isolation of bradykinin-potentiating peptides from Bothrops jararaca venom. Biochemistry ( 1970;) 9:: 2583–93.[CrossRef][Web of Science][Medline]
  11. Plosker GL, McTavish D. Captopril. A review of its pharmacology and therapeutic efficacy after myocardial infarction and in ischaemic heart disease. Drugs Aging ( 1995;) 7:: 226–53.[CrossRef][Web of Science][Medline]
  12. Stiles BG, Sexton FW, Weinstein SA. Antibacterial effects of different snake venoms: purification and characterization of antibacterial proteins from Pseudechis australis (Australian king brown or mulga snake) venom. Toxicon ( 1991;) 29:: 1129–41.[Medline]
  13. Oliveira CGT, Miranda FF, Ferreira VF, Freitas CC, Carballido JM, Corrêa LCD. Synthesis and antimicrobial evaluation of 3-hydrazino-naphthoquinones as analogs of lapachol. J Braz Chem Soc ( 2001;) 12:: 339–45.
  14. Fuly AL, de Miranda AL, Zingali RB, Guimaraes JA. Purification and characterization of a phospholipase A2 isoenzyme isolated from Lachesis muta snake venom. Biochem Pharmacol ( 2002;) 63:: 1589–97.[CrossRef][Web of Science][Medline]
  15. Izidoro LF, Ribeiro MC, Souza GR, Sant’Ana CD, Hamaguchi A, Homsi-Brandeburgo MI, et al. Biochemical and functional characterization of an L-amino acid oxidase isolated from Bothrops pirajai snake venom. Bioorg Med Chem ( 2006;) 14:: 7034–43.[CrossRef][Medline]
  16. Stabeli RG, Marcussi S, Carlos GB, Pietro RC, Selistre-de-Araujo HS, Giglio JR, et al. Platelet aggregation and antibacterial effects of an l-amino acid oxidase purified from Bothrops alternatus snake venom. Bioorg Med Chem ( 2004;) 12:: 2881–6.[CrossRef][Medline]
  17. Castro HC, Fernandes M, Zingali RB. Identification of bothrojaracin-like proteins in snake venoms from Bothrops species and Lachesis muta. Toxicon ( 1999;) 37:: 1403–16.[Medline]
  18. Gill SR. Insights on evolution of virulence and resistance from the complete genome analysis of an early methicillin-resistant Staphylococcus aureus strain and a biofilm-producing methicillinresistant Staphylococcus epidermidis strain. J Bact ( 2005;) 187:: 2426–38.[Abstract/Free Full Text]
  19. Elrick MM, Walgren JL, Mitchell MD, Thompson DC. Proteomics: recent applications and new technologies. Basic Clin Pharmacol Toxicol ( 2006;) 98:: 432–41.[Web of Science][Medline]
  20. Cushman DW, Ondetti MA. History of the design of captopril and related inhibitors of angiotensin converting enzyme. Hypertension ( 1991;) 17:: 589–92.[Free Full Text]
Received May 2, 2007; accepted July 16, 2008


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Ferreira, B. L.
Right arrow Articles by Castro, H. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ferreira, B. L.
Right arrow Articles by Castro, H. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?